Form 4 for SPRO Spero Therapeutics, Inc.
Accepted 2023-06-14 00:00:00 ET · period of report 2023-06-12 · accession 0000950170-23-027860 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-14 | 2023-06-12 | SPRO | HAMED KAMAL | Chief Medical Off | A - Grant | $0.00 | +140.0K | 616.0K | +29% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-12 | A | A | 140,000 | $0.00 | 615,957 | D | — | — | (F1) On August 4, 2022, the Reporting Person was granted a target of 140,000 performance-based restricted stock units ("RSUs") under the Issuer's 2019 Inducement Equity Incentive Plan, as amended. Each RSU represents the right, upon achievement of certain pre-established performance criteria, to receive one share of the Issuer's common stock, subject to vesting conditions. On June 12, 2023, the Board of Directors of the Issuer determined that 100% of the performance-based conditions were met resulting in 140,000 RSUs earned by the Reporting Person. The RSUs vest in two equal annual installments on September 12, 2023 and September 12, 2024, subject to the Reporting Person's continued service through the applicable vesting date. (F2) Consists of RSUs held by the Reporting Person. |